CSL delivers strong half year result and guidance upgrade

The CSL Limited (ASX:CSL) share price could be on the rise on Wednesday after delivering a strong half year result and upgrading its guidance…

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CSL Limited (ASX: CSL) share price will be on watch today following the release of its highly anticipated half year results.

What happened in the first half?

The biotherapeutics company has started FY 2020 very strongly and delivered an 11% increase in revenue to US$4,980 million in constant currency.

This was driven by an 10% increase in revenue from its CSL Behring business to US$3,768 million and a 9% lift in revenue from its Seqirus business to US$1,018 billion.

On the bottom line CSL delivered a reported net profit after tax of US$1,248 million for the six months ended December 31. This was an increase of 8%, or 11% on a constant currency basis.

The company's chief executive officer and managing director, Paul Perreault, was pleased with the half.

He said, "I am pleased to report a strong first-half result of the 2020 financial year. Our results reflect the focused execution of our strategy, robust demand for our differentiated medicines and a deep, inherent passion for meeting the evolving needs of our patients."

Segment performance.

The key CSL Behring business continued its strong growth thanks to an exceptional performance by its largest franchise, the immunoglobulin portfolio.

PRIVIGEN sales grew 28% and HIZENTRA sales jumped 37% due to continued strong patient demand, together with an expanded label claim. Both products now include Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), a debilitating neurological disorder.

This was supported by growth in Haemophilia and Specialty sales. Haemophilia sales were up 4% thanks to strong growth in recombinant sales, whereas Specialty sales lifted 7% due partly to solid Kcentra sales growth.

As expected, Albumin sales fell 33% during the half. This was due to CSL transitioning to its new direct distribution model in China. This offset double digit growth in Europe and Emerging Markets and a 5% lift in the United States.

The Seqirus influenza vaccines business delivered another strong performance. The main drivers of its growth were a 21% lift in QIV sales and a 21% increase in Adjuvanted sales. These represent 81% of Seqirus' total revenue.

Outlook.

In light of its strong first half performance, management has upgraded its profit guidance for the full year.

Mr Perreault explained: "CSL is well positioned for sustainable growth. Exceptional demand continues for our differentiated therapies. We expect to again outpace the market in expanding plasma collections and our objective to open 40 new collection centers this financial year is on track."

CSL now expects its FY 2020 net profit after tax in the range of US$2,110 million to US$2,170 million in constant currency. This represents growth of approximately 10% to 13% growth over FY 2019 and incorporates the one-off financial impact of transitioning to a new direct distribution model in China. The company's previous guidance was for growth of 7% to 10% in FY 2020.

Should you invest $1,000 in CSL right now?

Before you buy CSL shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and CSL wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 30 April 2025

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

Man holding a tray of burritos, symbolising the Guzman share price.
Share Market News

Wingstop mania hits Sydney — is Guzman y Gomez next in line to soar?

Can Guzman y Gomez be Australia’s next fast food success story on the ASX?

Read more »

A person sitting at a desk smiling and looking at a computer.
Share Market News

2 ASX small caps with serious market-beating potential

Here's two compelling ideas to add to your watchlist.

Read more »

A man holds his head in his hands, despairing at the bad result he's reading on his computer.
Share Market News

These are the 10 most shorted ASX shares

Let's see which shares short sellers are targeting this week.

Read more »

A young woman wearing a red and white striped t-shirt puts her hand to her chin and looks sideways as she wonders whether to buy NAB shares
Opinions

The pros and cons of buying Wesfarmers shares in May

Is this retail giant an appealing opportunity?

Read more »

A man looking at his laptop and thinking.
Share Market News

5 things to watch on the ASX 200 on Monday

Here's what to expect on the local market today.

Read more »

Five retirees do a conga line dance on the beach celebrating the special dividend announced by Grange Resources today
Broker Notes

Why Macquarie thinks the NZ retirement village sector could be an emerging opportunity for ASX investors

Oceania Healthcare and Summerset could quietly emerge as high-upside plays for patient ASX investors.

Read more »

Excited couple celebrating success while looking at smartphone.
Broker Notes

5 high-conviction ASX 200 shares to buy

Brokers are tipping these shares as buys. Here’s what they rate highly.

Read more »

A woman in a business suit sits at her desk with gold bars in each hand while she kisses one bar with her eyes closed. Her desk has another three gold bars stacked in front of her. symbolising the rising Northern Star share price
Gold

How this ASX All Ords gold stock turned $10,000 into $78,740 in just one year

The ASX All Ords gold miner has raced higher over the year. Let’s find out how.

Read more »